Print

Active Biotech AB Interim Report January - September 2011

2011-11-03

  • Laquinimod- Phase III BRAVO trial concluded. Teva plans an additional clinical study before filing a registration application in the US
  • TASQ- enrolment of patients for Phase III trial ongoing
  • TASQ- Phase II trial published in Journal of Clinical Oncology
  • ANYARA- Phase III trial proceeding according to plan
  • 57-57- a clinical trial in being prepared in systemic sclerosis
  • ISI- project is proceeding as planned
  • RhuDex® - preparations for continued clinical development ongoing
  • Net sales SEK 231.3 M (8.5)
  • Operating loss SEK 6.2 M (loss: 149.7)
  • Loss after tax SEK 1.3 M (loss: 156,8)
  • Loss per share for the period amounted to SEK 0,02 (loss: 2.40)

For further information, please contact:

Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95

Hans Kolam, CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0) 46-19 11 00

This report is also available at www.activebiotech.com


pdfActive Biotech AB Interim Report Jan-Sep 2011



Back